当前位置: 首页 >> 检索结果
6462. Lung cancer.
作者: Alesha A Thai.;Benjamin J Solomon.;Lecia V Sequist.;Justin F Gainor.;Rebecca S Heist.
来源: Lancet. 2021年398卷10299期535-554页
Lung cancer is one of the most frequently diagnosed cancers and the leading cause of cancer-related deaths worldwide with an estimated 2 million new cases and 1·76 million deaths per year. Substantial improvements in our understanding of disease biology, application of predictive biomarkers, and refinements in treatment have led to remarkable progress in the past two decades and transformed outcomes for many patients. This seminar provides an overview of advances in the screening, diagnosis, and treatment of non-small-cell lung cancer and small-cell lung cancer, with a particular focus on targeted therapies and immune checkpoint inhibitors.
6464. Estimating global and regional disruptions to routine childhood vaccine coverage during the COVID-19 pandemic in 2020: a modelling study.
作者: Kate Causey.;Nancy Fullman.;Reed J D Sorensen.;Natalie C Galles.;Peng Zheng.;Aleksandr Aravkin.;M Carolina Danovaro-Holliday.;Ramon Martinez-Piedra.;Samir V Sodha.;Martha Patricia Velandia-González.;Marta Gacic-Dobo.;Emma Castro.;Jiawei He.;Megan Schipp.;Amanda Deen.;Simon I Hay.;Stephen S Lim.;Jonathan F Mosser.
来源: Lancet. 2021年398卷10299期522-534页
The COVID-19 pandemic and efforts to reduce SARS-CoV-2 transmission substantially affected health services worldwide. To better understand the impact of the pandemic on childhood routine immunisation, we estimated disruptions in vaccine coverage associated with the pandemic in 2020, globally and by Global Burden of Disease (GBD) super-region.
6465. Measuring routine childhood vaccination coverage in 204 countries and territories, 1980-2019: a systematic analysis for the Global Burden of Disease Study 2020, Release 1.
Measuring routine childhood vaccination is crucial to inform global vaccine policies and programme implementation, and to track progress towards targets set by the Global Vaccine Action Plan (GVAP) and Immunization Agenda 2030. Robust estimates of routine vaccine coverage are needed to identify past successes and persistent vulnerabilities. Drawing from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2020, Release 1, we did a systematic analysis of global, regional, and national vaccine coverage trends using a statistical framework, by vaccine and over time.
6468. Mortality from gastrointestinal congenital anomalies at 264 hospitals in 74 low-income, middle-income, and high-income countries: a multicentre, international, prospective cohort study.
Congenital anomalies are the fifth leading cause of mortality in children younger than 5 years globally. Many gastrointestinal congenital anomalies are fatal without timely access to neonatal surgical care, but few studies have been done on these conditions in low-income and middle-income countries (LMICs). We compared outcomes of the seven most common gastrointestinal congenital anomalies in low-income, middle-income, and high-income countries globally, and identified factors associated with mortality.
6470. Progressive exercise compared with best practice advice, with or without corticosteroid injection, for the treatment of patients with rotator cuff disorders (GRASP): a multicentre, pragmatic, 2 × 2 factorial, randomised controlled trial.
作者: Sally Hopewell.;David J Keene.;Ioana R Marian.;Melina Dritsaki.;Peter Heine.;Lucy Cureton.;Susan J Dutton.;Helen Dakin.;Andrew Carr.;Willie Hamilton.;Zara Hansen.;Anju Jaggi.;Chris Littlewood.;Karen L Barker.;Alastair Gray.;Sarah E Lamb.; .
来源: Lancet. 2021年398卷10298期416-428页
Corticosteroid injections and physiotherapy exercise programmes are commonly used to treat rotator cuff disorders but the treatments' effectiveness is uncertain. We aimed to compare the clinical effectiveness and cost-effectiveness of a progressive exercise programme with a single session of best practice physiotherapy advice, with or without corticosteroid injection, in adults with a rotator cuff disorder.
6473. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey.
作者: Mine Durusu Tanriover.;Hamdi Levent Doğanay.;Murat Akova.;Hatice Rahmet Güner.;Alpay Azap.;Sıla Akhan.;Şükran Köse.;Fatma Şebnem Erdinç.;Emin Halis Akalın.;Ömer Fehmi Tabak.;Hüsnü Pullukçu.;Özgür Batum.;Serap Şimşek Yavuz.;Özge Turhan.;Mustafa Taner Yıldırmak.;İftihar Köksal.;Yeşim Taşova.;Volkan Korten.;Gürdal Yılmaz.;Mustafa Kemal Çelen.;Sedat Altın.;İlhami Çelik.;Yaşar Bayındır.;İlkay Karaoğlan.;Aydın Yılmaz.;Aykut Özkul.;Hazal Gür.;Serhat Unal.; .
来源: Lancet. 2021年398卷10296期213-222页
CoronaVac, an inactivated whole-virion SARS-CoV-2 vaccine, has been shown to be well tolerated with a good safety profile in individuals aged 18 years and older in phase 1/2 trials, and provided a good humoral response against SARS-CoV-2. We present the interim efficacy and safety results of a phase 3 clinical trial of CoronaVac in Turkey.
6476. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial.
作者: Christopher Sweeney.;Sergio Bracarda.;Cora N Sternberg.;Kim N Chi.;David Olmos.;Shahneen Sandhu.;Christophe Massard.;Nobuaki Matsubara.;Boris Alekseev.;Francis Parnis.;Vagif Atduev.;Gary L Buchschacher.;Rustem Gafanov.;Luis Corrales.;Michael Borre.;Daniil Stroyakovskiy.;Gustavo Vasconcelos Alves.;Evangelos Bournakis.;Javier Puente.;Marie-Laurence Harle-Yge.;Jorge Gallo.;Geng Chen.;Justin Hanover.;Matthew J Wongchenko.;Josep Garcia.;Johann S de Bono.
来源: Lancet. 2021年398卷10295期131-142页
The PI3K/AKT and androgen-receptor pathways are dysregulated in metastatic castration-resistant prostate cancers (mCRPCs); tumours with functional PTEN-loss status have hyperactivated AKT signalling. Dual pathway inhibition with AKT inhibitor ipatasertib plus abiraterone might have greater benefit than abiraterone alone. We aimed to compare ipatasertib plus abiraterone with placebo plus abiraterone in patients with previously untreated mCRPC with or without tumour PTEN loss.
|